✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹3,905 Cr.
P/E
21.31

Key Ratios

Market cap
Market cap
3,905 Cr
PE
PE
21.31
Prom Holding
Prom Holding
72.95 %
ROE (%)
ROE (%)
23.39
ROCE (%)
ROCE (%)
31.28
Div Yield (%)
Div Yield (%)
1.70
Sales
Sales
653 Cr
OPM (%)
OPM (%)
24.43 %
Debt to Equity
Debt to Equity
-
About
RPG Life Sciences, a part of RPG Enterprises, is an integrated pharmaceutical company operatin… Read more
Low
1515
52W Range
High
2975
  • RPG Life Sciences
  • Guj. Themis Biosyn
  • Advanced Enzyme
  • TJI Pharma - Small Cap

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

12 Yes

Positive for this company

1 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Product Wise Break-Up - Active Pharmaceutical Ingredients (API).

Product Wise Break-Up - Domestic Formulations

Location Wise Break-Up - International Formulations

Location Wise Break-Up

Customer Segment - International Formulations

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Corporate Actions
    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less
    Suppliers
    • Gulshan Polyols Ltd.
    • Zim Laboratories Ltd.
    FAQs on RPG Life Sciences Ltd. Business

    RPG Life Sciences is a research-based pharmaceutical company under RPG Enterprises. It operates in Branded Formulations, Global Generics, and Synthetic APIs markets, producing a wide range of quality and affordable medicines.

    RPG Life Sciences major competitors are Guj. Themis Biosyn, Advanced Enzyme, Aarti Drugs, Unichem Lab, Gufic Biosciences, Dishman Carbogen Amc, Orchid Pharma.
    Market Cap of RPG Life Sciences is ₹3,905 Crs.
    While the median market cap of its peers are ₹3,835 Crs.

    RPG Life Sciences seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing
    Discussions & Analysis
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material